SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.11-2.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (4487)8/17/2001 9:21:34 AM
From: Biomaven  Read Replies (1) of 52153
 
nigel,

I chatted with the Lion US CEO after a talk he gave at the Harvard Biotech club a while back. His comment at that time was that all the targets they and others were providing to Bayer were stretching Bayer's capabilities to advance them, and Bayer clearly needed to add substantial resources to take full advantage of all the targets it was getting.

It certainly does seem to me that Bayer was spending an awful lot on targets compared with the other pharmas.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News